LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals (NASDAQ: SNTA) – Ganetespib, a non-ansamycin inhibitor of Hsp90, enhances the activity of the microtubule targeting docetaxel, paclitaxel, and vincristine in multiple non-small cell lung cancer (NSCLC) xenograft models according to an article published in the journal Investigational New Drugs. Ganetespib is currently being studied in combination with docetaxel in a Phase 2b/3 clinical trial (GALAXY) in non-small cell lung cancer.
